Adjuvant trastuzumab in HER2-positive breast cancer.

ABSTRACT:

Background

Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.

Methods

We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety.

Results

At a median follow-up of 65 months, 656 events trigg

SUBMITTER: Slamon D 

PROVIDER: S-EPMC3268553 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature